Direct compression of Jililing Tablets Veterinary Grade API into tablet cores is specified only after the raw API lot has been characterized by sieve analysis through 100-mesh and 200-mesh screens, bulk density 0.45–0.65 g/cm³, and angle of repose below 35° using USP <1174>. The active fraction is calculated as target dose divided by core mass; for a target dose of 20 mg in a 200 mg core, the active fraction is 10.0% w/w, then adjusted for batch potency. A 1:1 pre-blend with microcrystalline cellulose is passed through a 500 µm screen before main blending to reduce API agglomeration. The main blend contains the pre-blend, spray-dried lactose monohydrate, croscarmellose sodium at 2.0–5.0% w/w, and magnesium stearate at 0.5–1.0% w/w; the magnesium stearate is added last and blended for 3–5 min in a 10 kg V-blender at 20 rpm and 60% fill volume. Over-lubrication is controlled because hydrophobic film formation on the API surface delays dissolution; if the magnesium stearate blend time exceeds 10 min, dissolution at 30 min may drop below the 75% Q value when tested by USP <711> apparatus 2 at 50 rpm. Compaction is carried out on a rotary press with 8 mm B-tooling at 6–10 kN compression force and 3–5 kN precompression force; target hardness is 40–80 N by USP <1217>. Ejection forces above 750 N trigger lubrication re-checks. Cores are tested by USP <701> disintegration with a 30 min limit in 37±2 °C water, USP <905> content uniformity with an acceptance value not greater than 15.0, and USP <711> dissolution; if friability by USP <1216> exceeds 1.0%, the tablet is not suitable for film coating.

Why Is Terminal Sterilization Preferred Over Aseptic Filling for Aqueous Injectable Solutions?

In aqueous injectable solution processing, Jililing Tablets Veterinary Grade API can be converted into a sterile injectable only when preformulation shows no more than 5% degradation under forced hydrolysis at pH 5.0 and 80 °C over 48 h; if this threshold is exceeded, alternative sterile dosage forms are required. For thermostable solutions, terminal sterilization is preferred because it provides a sterility assurance level not exceeding 1 × 10⁻⁶ and avoids aseptic line intervention risk. The bulk solution is prepared in water for injection, adjusted with 0.1 M hydrochloric acid or sodium hydroxide to the pH determined from kinetic solubility, and made isotonic with sodium chloride at 0.9% w/v. The solution is prefiltered through a 0.45 µm polyethersulfone membrane and sterilizing-filtered through a 0.22 µm PVDF filter into depyrogenated Type I glass vials that have been washed and dry-heat sterilized at 250 °C for 30 min. Stoppers are steam-sterilized at 121 °C for 15 min; closures are checked for integrity by vacuum decay. The filled containers are autoclaved at 121 °C for 15 min, which produces a theoretical F₀ of 15 min, above the minimum F₀ of 8 min stated in current sterilization guidelines. Finished vials are inspected under 2000–3750 lux against black and white backgrounds for visible particles per USP <790>; subvisible particles are counted by light obscuration per USP <788> with limits of 6000 particles per container at ≥10 µm and 600 particles per container at ≥25 µm for containers of 100 mL or less. Sterility is confirmed by membrane filtration per USP <71>, and bacterial endotoxin is controlled per USP <85> using a limit calculated from the veterinary dose, for example 0.5 EU/mg when the maximum dose is 20 mg/kg; this limit is product-specific and must be justified by the submission file. If the API exhibits pH-dependent hydrolysis or oxidative degradation in sparged oxygen, nitrogen blanketing and amber vials are introduced; otherwise colorless Type I glass remains acceptable.

Low-Dose Capsule Fill Weight Control and Excipient Loading

After geometric dilution is completed, low-dose encapsulation of Jililing Tablets Veterinary Grade API proceeds through a sequence designed to hold content uniformity at active fractions below 5% w/w of the fill weight. A 1:1 trituration with lactose monohydrate is passed through a 250 µm screen, then diluted stepwise to final fill weight in a 200 L bin blender at 12 rpm for 20 min. The fill matrix is adjusted to a bulk density of 0.6–0.8 g/cm³ and a tapped density not exceeding 1.0 g/cm³; Carr index is kept below 25% according to USP <1174>. Pregelatinized starch at 5–10% w/w and croscarmellose sodium at 2–5% w/w are used as disintegrants; magnesium stearate is limited to 0.5–1.0% w/w and blended for 3 min after all other excipients have been mixed. Capsule filling on a dosator-type machine with size 3 hard gelatin capsules requires pin height adjustment because low-fill-weight capsules with active fractions below 2% are sensitive to powder bed depth; fill weight ranges of 100–180 mg in size 3 are controlled with a checkweigher rejection limit of ±5%. HPMC capsules are substituted for gelatin when the powder bed moisture exceeds 6% by USP <921> or when aldehyde-containing carriers are present, to prevent cross-linking. Content uniformity is tested by USP <905>; dissolution is run in USP <711> apparatus 2 at 50 rpm using the product-specific monograph time point, and if the monograph specifies Q 75% at 45 min, the method must be discriminating enough to detect hardness-related dissolution failures. If the angle of repose exceeds 40° on a standard funnel, the formulation is switched to granulation because direct fill weight variation can exceed 6% RSD at press speeds above 30,000 capsules/h.

When medicated feed is the target, Jililing Tablets Veterinary Grade API is processed as a dry concentrated intermediate; the API is not added directly to final feed because direct addition of low-dose active fractions presents segregation risk. A two-stage dilution is used: a 1:9 step with ground corn cob or rice hull carrier, then a second 1:9 step with calcium carbonate to achieve the final premix concentration. Mineral oil at 0.5–2.0% w/w is sprayed into a ribbon blender at 30 rpm to bind fine API to the carrier and reduce dust; excessive mineral oil above 3.0% w/w causes bridging in screw conveyors and false assay results from non-homogeneous carrier wetting. Blending is performed in a horizontal ribbon mixer at 60–80% fill volume for 10–15 min; 10 thief samples are drawn from the mixer discharge and the relative standard deviation of assay values must be ≤ 5.0% before release. The premix is packaged in multi-wall paper bags with 0.5 mil low-density polyethylene liners; if moisture uptake above 8% by USP <921> is observed in stability chambers at 40 °C/75% RH, desiccant pouches are inserted and the bag seal is upgraded to foil laminate. Carryover is controlled by a cleanout sequence with 5–10 kg of ground corn cob after every batch; residual API in the next non-medicated batch must be below the limit set by medicated feed regulations, such as FDA 21 CFR 225 Good Manufacturing Practice for Medicated Feeds. Final feed dilution is calculated from the approved veterinary feed directive dose; a premix with 10,000 ppm active when included at 10 kg/tonne delivers 100 ppm in complete feed, and a second medicated feed batch must not be run before line flush validation is completed.

When Wet Granulation Is Selected for Oral Granules

If direct compression fails because the API lot shows poor flow or unacceptable bulk density, wet granulation is selected for Jililing Tablets Veterinary Grade API. The binder solution is prepared with povidone K30 at 2–5% w/w in purified water; high-shear mixing in a 10 L bowl proceeds at impeller 300 rpm and chopper 1500 rpm, with the endpoint determined by impeller power consumption rather than fixed time. The wet mass is passed through a 1.0 mm screen and dried in a fluid bed dryer with inlet air at 60–70 °C until moisture is 1.5–2.5% by USP <921>. Drying at product temperature above 50 °C or for extended periods may harden the granules and reduce dissolution. The dried granules are screened through 500 µm; oversize is milled with a cone mill at 1500 rpm using a 1.0 mm screen. Crospovidone intra-granular at 2% w/w and extra-granular at 2% w/w are split to balance disintegration and compaction. Final blend with magnesium stearate 0.5% w/w proceeds for 3 min. The finished granules are filled into sachets at target fill weight by a volumetric auger filler. Granule size distribution is measured by sieve stack 125, 250, 500, 1000 µm; the 150–500 µm fraction should exceed 80% to avoid segregation during filling. Dissolution of the sachet content is tested by USP <711> apparatus 2; if the API is poorly water-soluble, the dissolution medium may require surfactant but the method must be validated for discriminating ability.

For drinking water administration, Jililing Tablets Veterinary Grade API is converted into a soluble powder by blending with water-soluble carriers in a low-humidity area with relative humidity not exceeding 40%. The carrier matrix typically contains dextrose monohydrate as filler, citric acid anhydrous as pH modifier, sodium bicarbonate or sodium carbonate to adjust dissolution, and sodium chloride for ionic strength; the exact proportions are set by the target stock solution concentration and pH stability window. Colloidal silicon dioxide at 0.5–1.0% w/w is added as a glidant only if the angle of repose exceeds 40° by USP <1174>. The blend is mixed in a ribbon blender at 20 rpm for 15–20 min; because the API may segregate if bulk density differences exceed 0.2 g/cm³, carrier particle size is matched to the API by sieve analysis before scaling. The powder is filled into foil-lined heat-seal pouches of 1 kg, 5 kg, or 25 kg; headspace oxygen is evacuated and the seal is checked to ASTM D3078 leak test and ASTM F88 seal strength. Moisture content is controlled below 1.5% by USP <921> at release; if the product is exposed to 30 °C/65% RH for 24 h, moisture uptake must not exceed 0.3% over the initial value. For quality control, a 1.0% w/v solution of the powder in 20 °C water is considered acceptable when no visible undissolved particles remain after 5 min of stirring at 300 rpm; turbidity is measured by nephelometer and must be below the procedure-specified limit. If the API forms a supersaturated solution or crystallizes upon standing, the formulation is adjusted with a co-solvent or complexing agent, but the final powder must remain free-flowing.

Oral Solutions Are Not a Default Option for Poorly Water-Soluble APIs

Before oral solution compounding is initiated, the solubility profile of Jililing Tablets Veterinary Grade API is generated at 5 °C, 25 °C, and 40 °C in water, citrate buffer, and phosphate buffer; a true solution is acceptable only if the API concentration remains above the declared dose strength across all storage temperatures with no precipitation. Co-solvents such as propylene glycol at 10–30% v/v, glycerol at 5–20% v/v, and sorbitol solution at 20–40% v/v are used when aqueous solubility is insufficient; the co-solvent concentration must not exceed the acceptable daily intake established in VICH GL18 residual solvents for target species. Preservatives are added only after confirming that the API does not interact with paraben esters; methylparaben at 0.18% w/v and propylparaben at 0.02% w/v are common for oral liquids, and the formulation is challenged by antimicrobial effectiveness testing according to USP <51>, with bacterial counts reduced by not less than 1-log at 14 days and no increase at 28 days. The vehicle is mixed in a stainless-steel vessel with a low-shear propeller at 300 rpm; API is added after pH adjustment, not before, to avoid local precipitation in acidic microenvironments. Filtration through a 100 µm in-line strainer is performed before filling; amber polyethylene terephthalate bottles are selected if photostability data from ICH Q1B confirm light sensitivity. If the API has a solubility below the required dose or exhibits crystal growth in cyclic temperature studies between 5 °C and 40 °C, an oral suspension with xanthan gum at 0.1–0.3% w/v and wetting agent is prepared instead; the suspension is homogenized at 3000 rpm in a Silverson L5T and must show no caking after 7 days at room temperature.

Compliance Test Matrix Across Dosage Forms